M
Mark Kirschbaum
Researcher at City of Hope National Medical Center
Publications - 71
Citations - 5994
Mark Kirschbaum is an academic researcher from City of Hope National Medical Center. The author has contributed to research in topics: Romidepsin & Transplantation. The author has an hindex of 28, co-authored 71 publications receiving 5687 citations. Previous affiliations of Mark Kirschbaum include Hebrew University of Jerusalem & Penn State Milton S. Hershey Medical Center.
Papers
More filters
Journal ArticleDOI
Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases
Shimon Slavin,Arnon Nagler,Ella Naparstek,Yossi Kapelushnik,Memet Aker,Gabriel Cividalli,G. Varadi,Mark Kirschbaum,Aliza Ackerstein,Simcha Samuel,Avraham Amar,Chaim Brautbar,Ofira Ben-Tal,Amiram Eldor,Reuven Or +14 more
TL;DR: Preliminary data in 26 patients with standard indications for allogeneic BMT suggest that nonmyeloablative conditioning including fludarabine, anti-T-lymphocyte globulin, and low-dose busulfan is extremely well tolerated, with no severe procedure-related toxicity.
Journal ArticleDOI
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
Richard Piekarz,Robin Frye,Maria L. Turner,John Wright,Steven L. Allen,Mark Kirschbaum,Jasmine Zain,H. Miles Prince,John P. Leonard,Larisa J. Geskin,Craig B. Reeder,David Joske,William D. Figg,Erin R. Gardner,Seth M. Steinberg,Elaine S. Jaffe,Maryalice Stetler-Stevenson,Stephen Lade,A. Tito Fojo,Susan E. Bates +19 more
TL;DR: The histone deacetylase inhibitor romidepsin has single-agent clinical activity with significant and durable responses in patients with CTCL.
Journal ArticleDOI
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
Richard Piekarz,Robin Frye,H. Miles Prince,Mark Kirschbaum,Jasmine Zain,Steven L. Allen,Elaine S. Jaffe,Alexander Ling,Maria L. Turner,Cody J. Peer,William D. Figg,Seth M. Steinberg,Sonali M. Smith,David Joske,Ian D. Lewis,Laura F. Hutchins,Michael Craig,A. Tito Fojo,John J. Wright,Susan E. Bates +19 more
TL;DR: The histone deacetylase inhibitor romidepsin has single agent clinical activity associated with durable responses in patients with relapsed PTCL and supported the approval of romidepsypsin for CTCL.
Journal ArticleDOI
Results of the phase i trial of RG7112, a small-molecule MDM2 antagonist in leukemia
Michael Andreeff,Kevin R. Kelly,Karen W.L. Yee,Sarit Assouline,Roger Strair,Leslie Popplewell,David G. Bowen,Giovanni Martinelli,Mark Drummond,Paresh Vyas,Mark Kirschbaum,Swaminathan Padmanabhan Iyer,Vivian Ruvolo,Graciela M. Nogueras González,Xuelin Huang,Gong Chen,Bradford Graves,Steven Blotner,Peter Bridge,Lori Jukofsky,Steve Middleton,Monica Reckner,Ruediger Rueger,Jianguo Zhi,Gwen Nichols,Kensuke Kojima +25 more
TL;DR: This phase I study of RG7112 provides proof-of-concept that MDM2 inhibition restores p53 function and generates clinical responses in hematologic malignancies and demonstrates clinical activity against relapsed/refractory AML and CLL/sCLL.
Journal ArticleDOI
Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
Anas Younes,Anna Sureda,Dina Ben-Yehuda,Pier Luigi Zinzani,Tee Chuan Ong,H. Miles Prince,Simon J. Harrison,Mark Kirschbaum,Patrick B. Johnston,Jennifer Gallagher,Christophe Le Corre,Angela Shen,Andreas Engert +12 more
TL;DR: In the largest, prospective, multicenter, international trial conducted in heavily pretreated patients with HL who relapsed or were refractory to ASCT, panobinostat monotherapy demonstrated antitumor activity, resulting in durable responses.